Semaphorin 3A in Ankylosing Spondylitis

Hsien Tzung Liao, Yuh Feng Lin, Chung Tei Chou, Chang Youh Tsai

Research output: Contribution to journalArticle

Abstract

Background/Purpose: To determine serum semaphorin 3A (Sema 3A) levels in ankylosing spondylitis (AS). Methods: Serum Sema 3A was measured in 46 AS patients and 30 healthy controls (HCs). For the patients, we recorded demographic data, disease activity, functional index & global assessment, detected human leukocyte antigen-B27 (HLA-B27), and measured erythrocyte sedimentation rate (ESR) & C-reactive protein (CRP). Results: Sema 3A was higher in AS patients than in HCs (3.98 ± 2.57 vs. 1.34 ± 0.48 ng/ml, p = 0.013). Area under the curve (AUC) of standard receiver operating characteristic (ROC) has suggested that Sema 3A > 2 ng/ml is better to predict the higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, > 4) than ESR or CRP. There were good correlations between higher Sema 3A and uveitis, Schöber's test, as well as interstitial lung disease. AS patients undergoing anti-tumor necrosis factor therapies for 3 months exhibited a positive correlation of change in Sema 3A (δSema 3A) with disease activity fluctuation [δBASDAI, δBath Ankylosing Spondylitis Functional Index (BASFI) and δBath Ankylosing Spondylitis - Global score (BAS-G)]. Conclusion: Serum Sema 3A level was increased in AS patients and was inversely correlated to Schöber's test. Serum Sema 3A is better as a bio-marker than ESR or CRP to correlate with high disease activity in AS patients, and it is also a good indicator for monitoring disease activity and functional status during anti-TNF treatment. Also, Sema 3A may be taken as a predictor for extra-articular presentations in AS, but this needs further study to elucidate.

Original languageEnglish
JournalJournal of Microbiology, Immunology and Infection
DOIs
Publication statusPublished - Feb 2019

Fingerprint

Semaphorin-3A
Ankylosing Spondylitis
Blood Sedimentation
Baths
C-Reactive Protein
Serum
Uveitis
Interstitial Lung Diseases
HLA Antigens
ROC Curve
Area Under Curve
Tumor Necrosis Factor-alpha
Joints

Keywords

  • Ankylosing spondylitis
  • Biomarker
  • Bone remodeling
  • Osteoimmunology
  • Semaphorin 3A

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Semaphorin 3A in Ankylosing Spondylitis. / Liao, Hsien Tzung; Lin, Yuh Feng; Chou, Chung Tei; Tsai, Chang Youh.

In: Journal of Microbiology, Immunology and Infection, 02.2019.

Research output: Contribution to journalArticle

Liao, Hsien Tzung ; Lin, Yuh Feng ; Chou, Chung Tei ; Tsai, Chang Youh. / Semaphorin 3A in Ankylosing Spondylitis. In: Journal of Microbiology, Immunology and Infection. 2019.
@article{9d62c8443f60414abafb96048c67246b,
title = "Semaphorin 3A in Ankylosing Spondylitis",
abstract = "Background/Purpose: To determine serum semaphorin 3A (Sema 3A) levels in ankylosing spondylitis (AS). Methods: Serum Sema 3A was measured in 46 AS patients and 30 healthy controls (HCs). For the patients, we recorded demographic data, disease activity, functional index & global assessment, detected human leukocyte antigen-B27 (HLA-B27), and measured erythrocyte sedimentation rate (ESR) & C-reactive protein (CRP). Results: Sema 3A was higher in AS patients than in HCs (3.98 ± 2.57 vs. 1.34 ± 0.48 ng/ml, p = 0.013). Area under the curve (AUC) of standard receiver operating characteristic (ROC) has suggested that Sema 3A > 2 ng/ml is better to predict the higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, > 4) than ESR or CRP. There were good correlations between higher Sema 3A and uveitis, Sch{\"o}ber's test, as well as interstitial lung disease. AS patients undergoing anti-tumor necrosis factor therapies for 3 months exhibited a positive correlation of change in Sema 3A (δSema 3A) with disease activity fluctuation [δBASDAI, δBath Ankylosing Spondylitis Functional Index (BASFI) and δBath Ankylosing Spondylitis - Global score (BAS-G)]. Conclusion: Serum Sema 3A level was increased in AS patients and was inversely correlated to Sch{\"o}ber's test. Serum Sema 3A is better as a bio-marker than ESR or CRP to correlate with high disease activity in AS patients, and it is also a good indicator for monitoring disease activity and functional status during anti-TNF treatment. Also, Sema 3A may be taken as a predictor for extra-articular presentations in AS, but this needs further study to elucidate.",
keywords = "Ankylosing spondylitis, Biomarker, Bone remodeling, Osteoimmunology, Semaphorin 3A",
author = "Liao, {Hsien Tzung} and Lin, {Yuh Feng} and Chou, {Chung Tei} and Tsai, {Chang Youh}",
year = "2019",
month = "2",
doi = "10.1016/j.jmii.2017.07.001",
language = "English",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",

}

TY - JOUR

T1 - Semaphorin 3A in Ankylosing Spondylitis

AU - Liao, Hsien Tzung

AU - Lin, Yuh Feng

AU - Chou, Chung Tei

AU - Tsai, Chang Youh

PY - 2019/2

Y1 - 2019/2

N2 - Background/Purpose: To determine serum semaphorin 3A (Sema 3A) levels in ankylosing spondylitis (AS). Methods: Serum Sema 3A was measured in 46 AS patients and 30 healthy controls (HCs). For the patients, we recorded demographic data, disease activity, functional index & global assessment, detected human leukocyte antigen-B27 (HLA-B27), and measured erythrocyte sedimentation rate (ESR) & C-reactive protein (CRP). Results: Sema 3A was higher in AS patients than in HCs (3.98 ± 2.57 vs. 1.34 ± 0.48 ng/ml, p = 0.013). Area under the curve (AUC) of standard receiver operating characteristic (ROC) has suggested that Sema 3A > 2 ng/ml is better to predict the higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, > 4) than ESR or CRP. There were good correlations between higher Sema 3A and uveitis, Schöber's test, as well as interstitial lung disease. AS patients undergoing anti-tumor necrosis factor therapies for 3 months exhibited a positive correlation of change in Sema 3A (δSema 3A) with disease activity fluctuation [δBASDAI, δBath Ankylosing Spondylitis Functional Index (BASFI) and δBath Ankylosing Spondylitis - Global score (BAS-G)]. Conclusion: Serum Sema 3A level was increased in AS patients and was inversely correlated to Schöber's test. Serum Sema 3A is better as a bio-marker than ESR or CRP to correlate with high disease activity in AS patients, and it is also a good indicator for monitoring disease activity and functional status during anti-TNF treatment. Also, Sema 3A may be taken as a predictor for extra-articular presentations in AS, but this needs further study to elucidate.

AB - Background/Purpose: To determine serum semaphorin 3A (Sema 3A) levels in ankylosing spondylitis (AS). Methods: Serum Sema 3A was measured in 46 AS patients and 30 healthy controls (HCs). For the patients, we recorded demographic data, disease activity, functional index & global assessment, detected human leukocyte antigen-B27 (HLA-B27), and measured erythrocyte sedimentation rate (ESR) & C-reactive protein (CRP). Results: Sema 3A was higher in AS patients than in HCs (3.98 ± 2.57 vs. 1.34 ± 0.48 ng/ml, p = 0.013). Area under the curve (AUC) of standard receiver operating characteristic (ROC) has suggested that Sema 3A > 2 ng/ml is better to predict the higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, > 4) than ESR or CRP. There were good correlations between higher Sema 3A and uveitis, Schöber's test, as well as interstitial lung disease. AS patients undergoing anti-tumor necrosis factor therapies for 3 months exhibited a positive correlation of change in Sema 3A (δSema 3A) with disease activity fluctuation [δBASDAI, δBath Ankylosing Spondylitis Functional Index (BASFI) and δBath Ankylosing Spondylitis - Global score (BAS-G)]. Conclusion: Serum Sema 3A level was increased in AS patients and was inversely correlated to Schöber's test. Serum Sema 3A is better as a bio-marker than ESR or CRP to correlate with high disease activity in AS patients, and it is also a good indicator for monitoring disease activity and functional status during anti-TNF treatment. Also, Sema 3A may be taken as a predictor for extra-articular presentations in AS, but this needs further study to elucidate.

KW - Ankylosing spondylitis

KW - Biomarker

KW - Bone remodeling

KW - Osteoimmunology

KW - Semaphorin 3A

UR - http://www.scopus.com/inward/record.url?scp=85025454775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025454775&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2017.07.001

DO - 10.1016/j.jmii.2017.07.001

M3 - Article

AN - SCOPUS:85025454775

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

ER -